Treatment of Zollinger-Ellison Syndrome With Prevacid
|ClinicalTrials.gov Identifier: NCT00204373|
Recruitment Status : Completed
First Posted : September 20, 2005
Results First Posted : October 19, 2012
Last Update Posted : October 30, 2012
|Condition or disease||Intervention/treatment||Phase|
|Zollinger-Ellison Syndrome Multiple Endocrine Neoplasia||Drug: Lansoprazole (Prevacid)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||72 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors|
|Study Start Date :||March 2003|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
Experimental: single group
This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.
Drug: Lansoprazole (Prevacid)
Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
Other Name: Lansoprazole is marketed as Prevacid.
- Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment. [ Time Frame: up to 240 months from study enrollment ]number of participants with control of gastric acid production
- The Median Survival From the Time of Diagnosis. [ Time Frame: survival or up to 240 months ]The median survival from the time of diagnosis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00204373
|Principal Investigator:||C. Mel Wilcox, M.D.||University of Alabama at Birmingham|